Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
08 Février 2021 - 1:00PM
Business Wire
Extensive biotech finance and investor
relations expertise includes leadership roles at Editas Medicine
and Novartis
Vedanta Biosciences, a leading clinical-stage company developing
a new category of therapies for immune-mediated diseases based on
rationally defined consortia of human microbiome-derived bacteria,
today announced the appointment of Mark Mullikin as Chief Financial
Officer. Mr. Mullikin brings 25 years of experience raising and
deploying capital for life sciences companies, and most recently
held leadership roles in finance and investor relations at
publicly-traded Editas Medicine and Novartis.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210208005127/en/
Vedanta announced the appointment of Mark
Mullikin as Chief Financial Officer. Mr. Mullikin brings 25 years
of experience raising and deploying capital for life sciences
companies, and most recently held leadership roles in finance and
investor relations at publicly-traded Editas Medicine and Novartis.
(Photo: Business Wire)
“Mark’s experience overseeing the finances of a public biotech
and previously as a healthcare equity analyst, provide him a unique
and broad perspective of the biotech field,” said Bernat Olle,
Ph.D., Co-Founder and Chief Executive Officer of Vedanta
Biosciences. “We are excited to welcome Mark to the Vedanta team
and look forward to his contributions.”
Mr. Mullikin joins Vedanta from Editas Medicine, where he served
as Vice President, Finance and Investor Relations and was involved
in raising $700 million of equity capital. Prior to this role, Mr.
Mullikin worked for Novartis in roles focused on financial and
strategic planning in addition to health economics and pricing.
Before joining Novartis, he was a healthcare equity analyst at
Adage Capital Management and Piper Sandler and began his career in
the finance and strategy practice at Deloitte Consulting. Mr.
Mullikin earned his M.B.A. in finance from the MIT Sloan School of
Management and his B.A. in economics from the University of
Chicago.
“Vedanta has established a leadership position in the microbiome
field pioneering defined bacterial consortia as a new class of
therapeutics,” said Mr. Mullikin. “I am thrilled to join at this
pivotal moment of growth with key clinical trial readouts
anticipated this year.”
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies based on rationally defined
consortia of bacteria derived from the human microbiome. The
company’s clinical-stage pipeline includes product candidates being
evaluated for the treatment of high-risk C. difficile infection,
inflammatory bowel diseases, advanced or metastatic cancers, and
food allergy. These investigational therapies are grounded in
pioneering research – published in leading journals including
Science, Nature, and Cell – to identify beneficial bacteria that
live symbiotically within the healthy human gut, fight pathogens
and induce a range of potent immune responses. Vedanta Biosciences
controls a foundational portfolio of more than 40 patents and has
built what is believed to be the world’s biggest library of
bacteria derived from the human microbiome. Proprietary
capabilities include deep expertise in consortium design, vast
datasets from human interventional studies and cGMP-compliant
manufacturing of oral live biotherapeutics containing pure,
clonally derived bacterial consortia in powdered form. Vedanta
Biosciences was founded by PureTech Health (LSE: PRTC, Nasdaq:
PRTC) and a global team of scientific co-founders who pioneered
Vedanta’s modern understanding of the cross-talk between the
microbiome and the immune system.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210208005127/en/
Investors and Media
Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
Chris Brinzey +1 617 835 9304 Chris.Brinzey@westwicke.com
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024